{
  "paper": {
    "title": "SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade",
    "doi": "10.1038/s41586-025-09006-8",
    "publication_year": 2025,
    "domain": "oncology-immunology",
    "study_type": "preclinical+retrospective"
  },
  "core_question": "Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade therapy?",
  "datasets_or_cohorts": [
    {
      "id": "mouse-efficacy",
      "label": "Mouse efficacy cohort",
      "sample_size_or_observations": "78 mice",
      "description": "78 tumor‑bearing mice receiving combination of intratumoral mRNA vaccine and anti‑PD‑L1 therapy across repeat experiments."
    },
    {
      "id": "mouse-control",
      "label": "Mouse control cohort",
      "sample_size_or_observations": "84 mice",
      "description": "84 tumor‑bearing mice receiving vaccine‑only, ICI‑only, or vehicle control groups."
    },
    {
      "id": "human-retrospective",
      "label": "Human retrospective cohort",
      "sample_size_or_observations": "130 patients",
      "description": "130 metastatic cancer patients treated with immune checkpoint inhibitors, assessed by prior SARS‑CoV‑2 mRNA vaccination status."
    },
    {
      "id": "human-vaccinated",
      "label": "Vaccinated subgroup",
      "sample_size_or_observations": "43 patients",
      "description": "43 patients in the retrospective cohort who had received a SARS‑CoV‑2 mRNA vaccine before ICI therapy."
    },
    {
      "id": "human-unvaccinated",
      "label": "Unvaccinated subgroup",
      "sample_size_or_observations": "87 patients",
      "description": "87 patients in the retrospective cohort without prior mRNA vaccination."
    }
  ],
  "major_limitations": [
    "Retrospective human analysis is non‑randomized, risking confounding.",
    "Vaccination timing relative to ICI initiation varied across patients.",
    "Mouse model findings may not translate directly to all human tumors."
  ]
}